Laparoscopic combined with percutaneous ablation for hepatocellular carcinoma under liver capsule: A single Chinese center experience of thirty patients.

Laparoscopic combined with percutaneous ablation for hepatocellular carcinoma under liver capsule: A single Chinese center experience of thirty patients.
复制标题

腹腔镜联合经皮消融术治疗肝包膜下肝癌:中国单中心三十例患者经验。

DOI:
10.4103/0973-1482.200606
复制
发表时间:
2016-12
期刊:
J Cancer Res Ther
影响因子:
--
通讯作者:
Zhang Bo
Zhang Bo
中科院分区:
其他
文献类型:
--
作者:
Tang Zhe;Zhu Yi;Tang Kezhong;Dong Linping;Yang Bin;Fang Heqin;Wu Yulian;Zhang Bo

文献摘要

参考文献

相似文献

AIM OF STUDY For the tumor lesions close to capsule of the liver, traditional percutaneous radiofrequency ablation (PRFA) is limited due to high incidence of postoperative complications. The aim of the present study is to whether laparoscopic combined with PRFA (LCPR) could effectively ablate the tumor lesions close to capsule of the liver. METHODS A total of 119 patients with subcapsular hepatocellular carcinoma (HCC) were divided into two groups: PRFA group (89 patients) and LCPR group (30 patients). RFA was accomplished through cool-tip RFA system. For LCPR, PRFA was first carried out to destroy tumors deep inside the liver tissue. Then, laparoscopic RFA was performed under the guide of laparoscopic view and destroyed the superficial part of the tumor. Postoperative morbidity and technique effectiveness between two groups were evaluated. RESULTS In PRFA group, the rate of fever was 70.8% (63/89), and two patients had gallbladder damage. Five patients had ascites. Pain was found in 26 patients (29.2%). In LCPR group, the rate of fever was 22/30 (73.3%). Two patients had ascites and only two patients complained of pain. In PRFA group, 77.5% (69/89) of the tumors were totally ablated, and in LCPR, 93.3% (28/30) of the tumors were destroyed without any residuals. CONCLUSION LCPR could significantly reduce the incidence of postoperative pain and the rate of regional tumor residuals compared to the PRFA, suggesting this method could potentially be useful for subcapsular HCC ablation treatment.
DOI: 10.1111/hpb.12379
发表时间: 2015-05-01
期刊: HPB
影响因子: 2.9
作者:
de la Serna, Sofia;Vilana, Ramon;Garcia-Valdecasas, Juan-Carlos
通讯作者: Garcia-Valdecasas, Juan-Carlos